Search - tctmd.com

Displaying 61 - 80 of 397

Sort: Relevancy | Date

News Daily News

Features of Complex CAD Carry Progressive Risk in PCI, Registry Confirms

Caitlin E. Cox

October 08, 2020

News Conference News EuroPCR 2020

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

Todd Neale

June 30, 2020

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

L.A. McKeown

March 09, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

Balloon-Free PCI for SVG Stenosis Offers Ongoing Advantages: DIVA

Caitlin E. Cox

February 11, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Industry News

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that Luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

May 23, 2019

News Industry News

Latest generation DES: ANGIOLITE trial 24-month outcomes revealed at EuroPCR 2019 the non-inferiority of angiolite vs the gold standard EES

May 23, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

Advertisement

Features of Complex CAD Carry Progressive Risk in PCI, Registry Confirms

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Balloon-Free PCI for SVG Stenosis Offers Ongoing Advantages: DIVA

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

Lutonix BTK Studies: Below-the-Knee Challenges Linger

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that Luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

Latest generation DES: ANGIOLITE trial 24-month outcomes revealed at EuroPCR 2019 the non-inferiority of angiolite vs the gold standard EES

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content